• FamiCord signed a manufacturing agreement with Verigraft to support a pivotal Phase II/III trial for its P-TEV vein graft.
• Work covers process transfer, GMP manufacturing setup in Warsaw, tissue sourcing support; contract runs about 18 months.
• Estimated initial contract value sits in the low single-digit millions of euros, tied to trial progress and manufacturing demand.
• Phase II/III trial TECVI-2 is expected to start in Q1 2027, with sites planned in Spain, Poland, the Netherlands.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Famicord AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2404822_en) on September 24, 2026, and is solely responsible for the information contained therein.